A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether E7820 is an effective treatment for
people with relapsed/refractory myeloid cancers with mutations in splicing factor genes.
Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or
chronic myelomonocytic leukemia (CMML).